Navigation Links
Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments
Date:5/5/2008

- LymphoStat-B(R) Phase 3 trial BLISS-52 completes enrollment ahead of

previous fall 2008 projection - - Albuferon(R) Phase 3 trial in genotypes 2 and 3 hepatitis C completes

treatment phase -

- Rights to TRAIL receptor antibodies reacquired -

- GlaxoSmithKline announces plan to advance darapladib to Phase 3

development for the treatment of atherosclerosis -

ROCKVILLE, Md., May 5 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced financial results and key developments for the quarter ended March 31, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO )

"We have continued to make substantial progress toward the commercialization of our lead products since the beginning of 2008," said H. Thomas Watkins, President and Chief Executive Officer, HGS. "In April, we completed the enrollment of BLISS-52, one of our two Phase 3 trials of LymphoStat-B. We now expect to have our first Phase 3 data for LymphoStat-B available by mid-2009. We have completed the treatment phase in ACHIEVE 2/3, one of our two Phase 3 trials of Albuferon, and are on track to have our first Phase 3 data available for Albuferon late this year. We are also investing strategically in our oncology program, a potential key driver of future growth beyond our late-stage products. In April, we reacquired rights to our TRAIL receptor antibodies and announced plans to begin our third randomized chemotherapy combination trial of HGS-ETR1. In addition, darapladib, a product in the GlaxoSmithKline clinical pipeline to which we have substantial fina
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Pioneer(R) Surgical Technology Announces First Human Implants of its NuNec(TM) Cervical Arthroplasty Device
2. China Biologic Products Announces SFDA Approval for the Production of Cryoprecipitate and for the Clinical Trial of Human Prothrombin Complex
3. Human Genome Sciences to Sponsor Conference Call to Discuss First Quarter 2008 Financial Results
4. Identity Sciences Introduces a New, Fast Forensic Human I.D. Test
5. Human Genome Sciences Advances Oncology Portfolio
6. AMDL Signs Exclusive Licensing Agreement for Human Papilloma Virus Diagnostic Test Kit in Certain Asian Countries
7. Human Pheromone Sciences Announces Quarterly and Full Year Results
8. CryoLife Announces Implant of First FDA-Cleared SynerGraft(R) Processed Human Pulmonary Heart Valve
9. Oregon Health Care Quality Corporation Receives Important Designation from U.S. Department of Health and Human Services
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Cowen Conference
11. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Lehman Brothers Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... , Oct. 20, 2014 Mapp ... experimental ZMapp™ antibody therapeutic to fight the Ebola ... difficult and time-consuming the production of pharmaceuticals can ... research publisher said that while some may be ... this compound, those with industry knowledge are well ...
(Date:10/20/2014)... Calif. , Oct. 20, 2014 ... that the Company has signed a Notice of ... Regenerative Medicine (CIRM), effective October 1, 2014.  The ... Development payments and the release of additional grant ... CIRM grant award for clinical development of Asterias, ...
(Date:10/20/2014)... 2014 , A major pan-European ... the delivery of care has revealed changing trends in ... in the provision of healthcare services across the continent. ... United European Gastroenterology (UEG), have been announced today and ... of the burden of GI disorders across ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5
... 2008 at this year,s liver ... 4, SAN FRANCISCO, Oct. 27 Nonalcoholic steatohepatitis,(NASH) ... approved,medical therapy for this chronic progressive liver disease. Researchers,tested ... program. To do so, 31 overweight or obese patients ...
... Oct. 27 Carna Biosciences, Inc. ("Carna"),announced on ... Agreement with,Shanghai Universal Biotech Company ("SUBC"). Under the ... distributor of Carna,s Protein,Kinases within China., With ... in,the life sciences, major biopharmaceutical companies have now ...
... BioAtom Inc. (private) announced,today that it will present ... 28, 2008 at 2:30 PM PDT (5:30 PM EDT) ... Myron Karasik, M.B.A., C.M.C., Director of Finance, will ... Costa Mesa, CA, dedicated,to development and commercialization of Neutron ...
Cached Biology Technology:Intensive Lifestyle Intervention Program for Overweight or Obese Patients with Nonalcoholic Steatohepatitis Reduces Weight and Improves Overall Liver Health 2Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company 2BioAtom Inc. To Present at BIOCOM Investor Conference 2008 2
(Date:10/14/2014)... Like discriminating thieves, prostate cancer tumors scavenge and hoard ... But such avarice may be a fatal weakness. ... to kill prostate cancer cells by delivering a trove ... the diseased cells brimming with the mineral, leaving non-cancer ... drugs already commercially available for other uses, could soon ...
(Date:10/14/2014)... (Oct. 14, 2014)—It,s been millions of years since ... team led by Ohio University scientists is breathing life ... airflow through dinosaur snouts. The research has important implications ... breathe but to enhance the sense of smell and ... animals," said Ohio University doctoral student Jason Bourke, lead ...
(Date:10/14/2014)... to produce enough food to feed the world in ... of the United Nations predicts that food production must ... a growing global population, and plants are one major ... Plants—grains, cereals, fruits, vegetables, and more—feed humans directly and ... into our knowledge of how plants work to develop ...
Breaking Biology News(10 mins):Prostate cancer's penchant for copper may be a fatal flaw 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3
... a celebrity living on mineral water, the glassy-winged sharpshooter ... in California, which is feverishly working to prevent the ... a surprising study published in the June 6 issue ... at The Institute for Genomic Research (TIGR), the University ...
... here have discovered a new mechanism used by cells ?and ... proteins, including some involved in cancer. , The mechanism ... made by the cell. , The study by researchers ... James Cancer Hospital and Richard J. Solove Research Institute and ...
... two frog species feared extinct has made a new ... save amphibians from a deadly fungus decimating their populations ... the two Critically Endangered frogs ?the Santa Marta harlequin ... (Atelopus nahumae) ?for the first time in 14 years ...
Cached Biology News:Surprising symbiosis: Glassy-winged sharpshooter eats with friends 2Surprising symbiosis: Glassy-winged sharpshooter eats with friends 3Scientists discover new regulating mechanism in cells 2Scientists discover new regulating mechanism in cells 3Race to halt global amphibian crisis boosted by rediscovery of endangered Colombian frogs 2Race to halt global amphibian crisis boosted by rediscovery of endangered Colombian frogs 3
... Platypus Contact Printing Kit contains choice ... with series of 100 / 200 micron ... or 200 um x 10 mm lines, ... 20, 40 or 60 nm and pitch ...
...
... 5 ml of DETACHaBEAD Mouse CD4, polyclonal ... T cells from Dynabeads Mouse CD4 (L3T4). ... cells from Dynabeads Mouse CD4 using DETACHaBEAD ... for any downstream application including flow cytometry, ...
RECOMBINANT EQUINE IL-4 Product Type: Recombinant Protein...
Biology Products: